What question did this study set out to answer?

To review the pharmacokinetic, pharmacodynamic, and biochemical mechanisms underlying anthracycline-induced cardiotoxicity and correlate them with clinical cardiac phenotypes and prevention strategies.

June 2, 2011Expert Opinion on Drug Safety

Anthracycline cardiotoxicity

View Full Paper

Ask AI

Bookmark

To review the pharmacokinetic, pharmacodynamic, and biochemical mechanisms underlying anthracycline-induced cardiotoxicity and correlate them with clinical cardiac phenotypes and prevention strategies.
Synthesized translational preclinical and clinical literature examining anthracycline bioactivation pathways, reactive oxygen species formation, and secondary alcohol metabolite generation.
Evaluated clinical modifiers of cardiotoxicity risk, including concurrent chemotherapies, targeted agents, preexisting comorbidities, and lifestyle factors.
Anthracycline cardiotoxicity is driven by bioactivation cascades yielding reactive oxygen species and long-lived secondary alcohol metabolites that impair myocardial function across a patient's lifespan.
Patient comorbidities, adverse lifestyle choices, and co-administration with nonanthracycline or targeted therapies significantly amplify lifetime cardiotoxic risk.
Cardioprotective interventions and individualized risk factor management allow clinicians to maintain the therapeutic utility of anthracyclines without compromising cancer outcomes.

Structured PICO

Population

Cancer patients and survivors receiving anthracyclines

Intervention

Anthracyclines

Outcome

Cardiotoxicitysafety

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Anthracycline cardiotoxicity is multifactorial, but its risk should not preclude anthracycline use in oncology when cardioprotective strategies are pragmatically applied.

Cite This Study

Menna et al. (2011) studied this question.

synapsesocial.com/papers/6a76e91e6789de8d0af6e485 https://doi.org/10.1517/14740338.2011.589834

Topics

Cardio-oncology

View Full Paper

Ask AI

Bookmark

Implication

Anthracycline cardiotoxicity is multifactorial, but its risk should not preclude anthracycline use in oncology when cardioprotective strategies are pragmatically applied.

Anthracycline cardiotoxicity

Key Points

Structured PICO

Discussion

Implication

Cite This Study

Topics

Anthracycline cardiotoxicity

Key Points

Structured PICO

Discussion

Implication

Cite This Study

Also Consider

Topics

Also Consider